SK12593A3 - Medicament for therapy of neurological and psychical disorders, caused by an abusing of alcohols - Google Patents

Medicament for therapy of neurological and psychical disorders, caused by an abusing of alcohols Download PDF

Info

Publication number
SK12593A3
SK12593A3 SK12593A SK12593A SK12593A3 SK 12593 A3 SK12593 A3 SK 12593A3 SK 12593 A SK12593 A SK 12593A SK 12593 A SK12593 A SK 12593A SK 12593 A3 SK12593 A3 SK 12593A3
Authority
SK
Slovakia
Prior art keywords
thiamine
medicament according
acid
medicament
pharmacologically
Prior art date
Application number
SK12593A
Other languages
English (en)
Slovak (sk)
Inventor
Dieter Loew
Claus-Peter Haller
Fritz Worwag
Original Assignee
Worwag Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worwag Pharma Gmbh filed Critical Worwag Pharma Gmbh
Publication of SK12593A3 publication Critical patent/SK12593A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
SK12593A 1992-02-29 1993-02-22 Medicament for therapy of neurological and psychical disorders, caused by an abusing of alcohols SK12593A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19924206422 DE4206422C2 (de) 1992-02-29 1992-02-29 Arzneimittel zur Prophylaxe und Therapie von neurologischen und psychiatrischen Schäden durch Alkoholmißbrauch

Publications (1)

Publication Number Publication Date
SK12593A3 true SK12593A3 (en) 1993-09-09

Family

ID=6452953

Family Applications (1)

Application Number Title Priority Date Filing Date
SK12593A SK12593A3 (en) 1992-02-29 1993-02-22 Medicament for therapy of neurological and psychical disorders, caused by an abusing of alcohols

Country Status (6)

Country Link
EP (1) EP0558960A1 (hu)
CZ (1) CZ22693A3 (hu)
DE (1) DE4206422C2 (hu)
HU (1) HU213095B (hu)
PL (1) PL171450B1 (hu)
SK (1) SK12593A3 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713088B1 (fr) * 1993-12-03 1996-03-22 Bernard Aranda Utilisation de la vitamine B1 et ses dérivés pour la préparation d'un médicament destiné au traitement des affections dont les symptômes sont attribués aux désordres d'origine vasculaire.
DE19629803A1 (de) * 1996-07-24 1998-01-29 Woerwag Pharma Gmbh Arzneimittel zur Behandlung von Neuropathien
DE19629802A1 (de) * 1996-07-24 1998-01-29 Woerwag Pharma Gmbh Arzneimittel zur Behandlung von Neuropathien
GB9906740D0 (en) 1999-03-23 1999-05-19 Kilgowan Limited Oral combinations of hydroxocobalamin and folic acid
US20020094970A1 (en) * 2000-12-14 2002-07-18 Ronenn Roubenoff Compositions and methods for treating an arthritic condition
US8142799B2 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco High potency clinical anti-craving treatment and method of use
US8142800B1 (en) * 2001-12-18 2012-03-27 Tamea Rae Sisco Oral high potency clinical anti-craving treatment and method of use
DE102018129085A1 (de) 2018-11-19 2020-05-20 Alexander Raßmann Zusammensetzung zur Verbesserung des Carbonsäurestoffwechsels, Verwendung dieser und Zubereitung mit der Zusammensetzung

Also Published As

Publication number Publication date
DE4206422C2 (de) 1996-07-11
HU213095B (en) 1997-02-28
HUT64230A (en) 1993-12-28
HU9300534D0 (en) 1993-05-28
EP0558960A1 (de) 1993-09-08
DE4206422A1 (de) 1993-09-02
PL297880A1 (en) 1993-12-13
CZ22693A3 (en) 1993-12-15
PL171450B1 (pl) 1997-04-30

Similar Documents

Publication Publication Date Title
Douglas et al. Metabolic effects of recombinant human growth hormone: isotopic studies in the postabsorptive state and during total parenteral nutrition
Krecic‐Shepard et al. Gender‐specific effects on verapamil pharmacokinetics and pharmacodynamics in humans
Poo et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study
Bell et al. S‐adenosylmethionine blood levels in major depression: changes with drug treatment
NELSON et al. Phenobarbital pharmacokinetics and bioavailability in adults
JPH11116482A (ja) ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法
EP1603580B1 (en) Composition for administration of iron for the treatment of restless legs syndrome
Bertilsson et al. Pharmacokinetics: time‐dependent changes—autoinduction of carbamazepine epoxidation
CHALHUB et al. Phenytoin‐induced dystonia and choreoathetosis in two retarded epileptic children
SK12593A3 (en) Medicament for therapy of neurological and psychical disorders, caused by an abusing of alcohols
JP2004501964A (ja) 新規な葉酸代謝拮抗薬の組み合わせ療法
Georges et al. Metabolic effects of propranolol in thyrotoxicosis. I. Nitrogen, calcium, and hydroxyproline
Wood et al. Drug-induced psychosis and depression in the elderly
US20050215625A9 (en) Combination therapy for anticoagulation
McDonald et al. Parenteral methotrexate in psoriasis: A report on the efficacy and toxicity of long-term intermittent treatment
JP2023500360A (ja) Ｎ－アセチルシステインの鼻腔内投与のための用量、製剤、およびデバイスを較正および選択するための磁気共鳴分光法の使用
Gahm et al. Chronic cerebellar stimulation for cerebral palsy: a double‐blind study
Kirkemo et al. Serum vitamin level maintenance in cancer patients on total parenteral nutrition
Marcus et al. Digoxin bioavailability: Formulations and rates of infusions
Cradock et al. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate
US20020010148A1 (en) Oral combinations of hydroxocobalamin and folic acid
Giffard et al. Secobarbital Attenuates Excitotoxicity but Potentiates Oxygen—Glucose Deprivation Neuronal Injury in Cortical Cell Culture
Leppik Phenytoin
SHAH et al. Urinary excretion of citrate in humans following administration of acetazolamide (diamox)
Clancy et al. Neonatal theophylline neurotoxicity